Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time
July 29 2021 - 8:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse disease,
today announced that the Company will report its financial results
for the three months ended June 30, 2021, on Thursday, August 5,
2021, at 4:30 p.m. (ET). To join the live conference call, please
refer to the dial-in information provided below.
Dial-in information: U.S. Toll-Free:
844-369-8774International: 862-298-0844
A live webcast of the call will be available on the Caladrius
website under the Investors & News section. A replay of the
webcast will also be available for 90 days following the conclusion
of the call.
For those unable to participate on the live conference call, an
audio replay will be available that day starting at 7:30 p.m. (ET)
until August 19, 2021, by dialing 877-481-4010 (U.S. Toll-Free) or
919-882-2331 (International) and by entering the replay passcode:
42180.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study (www.freedom-trial.com) in the U.S.
for the treatment of coronary microvascular dysfunction (“CMD”);
CLBS12 (HONEDRA® in Japan), recipient of orphan designation
for Buerger’s Disease in the U.S. as well as SAKIGAKE
designation and eligible for early conditional approval in Japan
for the treatment of critical limb ischemia (“CLI”) and Buerger’s
Disease based on the results of an ongoing clinical trial; CLBS201,
designed to assess the safety and efficacy of CD34+ cell therapy as
a treatment for diabetic kidney disease (“DKD”); and OLOGO™
(CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”)
designated therapy for which the Company is in discussion with the
FDA to finalize a Phase 3 protocol of reduced size and scope for a
confirmatory trial in subjects with no-option refractory disabling
angina (“NORDA”). For more information on the Company, please
visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryRachel GirardReal ChemistryPhone:
401-477-4030Email: rgirard@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024